RBFC
AMPH icon

Roman Butler Fullerton & Co’s Amphastar Pharmaceuticals AMPH Stock Holding History

Roman Butler Fullerton & Co’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-24,710
Closed -$1.54M – 183
2023
Q2 		$1.54M Buy
+24,710
New +$1.1M 0.71% 37

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Roman Butler Fullerton & Co's AMPH Position: Q3 2023 in Review

Roman Butler Fullerton & Co sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2023, closing a stake of 24,710 shares — an estimated $1.54M sold.

Roman Butler Fullerton & Co first reported a position in AMPH in Q2 2023 and held it in 1 quarter. The position peaked at $1.54M in Q2 2023. 255 funds tracked by Wall St. Rank hold AMPH as of Q3 2023.

  • Roman Butler Fullerton & Co reported no remaining Amphastar Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 24,710 Amphastar Pharmaceuticals shares in Q3 2023, an estimated $1.54M.
  • Roman Butler Fullerton & Co first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Roman Butler Fullerton & Co's Amphastar Pharmaceuticals position peaked at $1.54M in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2023.

Based on Roman Butler Fullerton & Co's 13F filing for Q3 2023, filed 18 Oct 2023.